What are the Current Therapeutic Approaches for KRAS-Mutated Cancers?
Current therapeutic strategies for KRAS-mutated cancers include the use of direct KRAS inhibitors, targeting downstream effectors in the RAS/MAPK pathway, and employing combination therapies. Examples of direct KRAS inhibitors in clinical trials include sotorasib (AMG 510) and adagrasib (MRTX849). Additionally, targeting the MEK and ERK pathways are being explored.
